- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06447675
Effekt- og sikkerhedsevaluering af hypertermiske bade til behandling af anfald hos børn med CDKL5-mangel
Effekt- og sikkerhedsevaluering af hypertermiske bade til behandling af anfald hos børn med CDKL5-mangel: Et enkeltcenter, selvkontrolforsøg
The primary objective of this research is to study the efficacy and safety of hyperthermic baths as adjunctive therapy for reducing the frequency of seizures in CDKL5 deficiency.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This project aims to include 8 participants, and evaluate the effectiveness and safety of hyperthermic baths in patients with CDKL5 deficiency through A single-center, preliminary feasibility clinical trial. It is expected to provide new therapeutic options for patients with CDKL5 deficiency with alternative treatment options.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100053
- Xuanwu Hospital,Capital Medical University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- A diagnosis of CDKL5 deficiency, including molecular confirmation of a pathogenic or likely pathogenic CDKL5 variant and refractory seizures
- Male or female participants aged 6 months to less than 6 years
- Parent(s) or LAR willing to give written informed consent, after being properly informed of the nature and risks of the study and prior to engaging in any study-related procedures
- Failure to control seizures despite appropriate trial of 2 or more anti-seizure medications at therapeutic doses
- Have a history of at least 8 countable seizures per 4 weeks during the 8 weeks prior to screening. Countable seizures will be defined by the following:Seizures with or without impairment of consciousness with a clear motor component, including generalized tonic-clonic, focal to bilateral tonic-clonic, atonic, bilateral clonic, bilateral tonic, focal motor seizures with or without impaired awareness, or infantile spasms. Clusters of infantile spasms/tonic seizures will be counted as a single seizure.
- Participants should be on a stable regimen of anti-seizure medications for ≥ 4 weeks prior to the screening visit, without a foreseeable change in dosing for the duration of the DB phase.
- Vagus nerve stimulator (VNS) are permitted, but should be implanted for 1 year prior to screening and settings should be unchanged throughout the study.
- Parent/caregiver is able and willing to maintain an accurate and complete daily seizure eDiary for the duration of the study.
Exclusion Criteria:
- Any history of previous brain disease (trauma, etc.) that likely to precipitate seizures.
- Tissue damage (eczema, etc.) in the area where hyperthermic baths will be applied on the skin.
- Seizures associated with hyperthermic baths.
- Presence of any clinical condition that in the opinion of the principal investigator makes the patient not suitable to participate in the trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Hyperthermic Baths
Patients with CDKL5 deficiency assigned to hyperthermic baths will have their body immersed in a hot water (40~42°C) bath for 20 min per session. |
The intervention will consist of 12 weeks of repeated, daily 20-min body immersions. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Seizure frequency (SF28)
Tidsramme: Up to 12 week after hyperthermic baths
|
Seizure frequency (SF28) is defined as seizure count per month (28-day) period. The SF28 is calculated as follows, where D=total number of days for which seizure information is collected for the specific 28-day interval: SF28=(Total number of seizures in D days/D)*28. In addition, the baseline seizure frequency is defined as SF28 in the baseline period. The seizure frequency in the treatment phase is defined as SF28 per month during the treatment period. Percent change in seizure frequency=100*(treatment SF28-baseline SF28)/baseline SF28. |
Up to 12 week after hyperthermic baths
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Seizure Responder Rate
Tidsramme: Up to 12 week after hyperthermic baths
|
The proportion of patients with a ≥ 25%, ≥50% reduction from Baseline in seizure frequency. |
Up to 12 week after hyperthermic baths
|
|
Seizure-free Days
Tidsramme: Up to 12 week after hyperthermic baths
|
Seizure-free days over the entire treatment phase |
Up to 12 week after hyperthermic baths
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Liankun Ren, MD, Xuanwu Hospital, Beijing
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2024-111-002
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .